Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

Benzinga Newsdesk www.benzinga.com Neutral 56.4%

Neg 0% Neu 56.4% Pos 0%

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.